Low-dose computed tomography and rapid molecular sputum testing in adults with suspected non-ventilator-associated hospital-acquired pneumonia: the HAP-FAST pilot sequential multiple assignment randomised trial with embedded qualitative and costing studies
Year: 2026
Type: preprint
Study design: Clinical Trial
Abstract: Background Non-ventilator-associated hospital-acquired pneumonia (nv-HAP) diagnosis is imprecise; chest x-rays (CXR) lack detail and sputum culture delays targeted prescribing. However, the evidence base to support diagnostic improvement is sparse. We assessed the feasibility of a trial of low-dose thoracic CT and rapid molecular testing of sputum. Methods HAP-FAST was a UK NIHR funded, open-label pilot sequential multiple assignment randomised trial with qualitative and costing substudies in four UK hospitals (ClinicalTrials.gov: NCT05483309 ). Using research without prior consent (RWPC) and site-stratified web-based randomisation, clinicians allocated adults with suspected nv-HAP (excluding pregnancy and palliation), before their second antibiotic dose, 1:1 to CT or CXR; participants subsequently treated for nv-HAP with sputum available underwent another 1:1 randomisation to BIOFIRE ® FILMARRAY ® Pneumonia plus Panel (FAPP) with standard microbiology or standard microbiology alone . Feasibility outcomes included recruitment, consent, intervention delivery and data completeness through 90 days. Adverse events were not systematically collected. Analyses were intention-to-treat and descriptive. Results Between June 2023 and March 2024, 220 adults were randomised at stage-1 (109 CT; 111 CXR), reaching target three months early. Of 154/220 (70.0%) subsequently managed as nv-HAP, 92/154 (59.7%) could not produce sputum. 62/154 (40.3%; 28.2% of stage-1) were randomised to stage-2: 31 FAPP and 31 no-FAPP. Allocated imaging was recorded for 75/109 (68.8%) CT and 99/111 (89.2%) CXR participants; 6/31(19.4%) FAPP tests were not completed. Consent for follow-up was obtained for 142/220 (64.5%). Protocol-defined clinical cure was assessable in 1/220 participants. The day-90 resource-use questionnaire was returned by 55/110 participants (50.0%). Qualitative findings supported RWPC but identified needs for staged communication, lower-burden follow-up and improved diagnostic pathways. Excess bed days and readmissions drove costs but data capture requires refinement. Conclusions A definitive trial is plausible only with enhanced RWPC, diagnostic delivery and follow-up pathways, improved sputum procedures, stewardship-aligned outcomes and routine economic data capture.
Source: medRxiv
Authors: Dan G Wootton, Frances C Sherratt, Ian Powell, Simon T Abrams, Emini Adegbenro, Anica Alvarez Nishio, Stephen J Aston, Rohit Bazaz, Helen Clay, Ashley M Collins, Karl Cook, Andy Cross, Kerry Edwards, Patrick Evans, Fred Fyles, Nicola Goddard, Anja N Guldemond, James Hare, Alexander Howard, John Howells, Juliette Hucker-Shaw, Karen Irwin, Tom Jenks, Kurian Kalapurakal, Fatima Khalid, Emily Lam, Danielle Mclaughlan, Christopher McLeavy, Becci Pearce, Laura Pilling, Irene Poku, Natalia Shafiqa, Himanshu Singh, Amy Tao, Erica Thwaite, Sam Trewick, Lance Turtle, Stephanie Willshaw, Joseph Wood, Bridget Young, Ashley Jones
Institutions: University of Liverpool, Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Warrington and Halton Teaching Hospitals NHS Foundation Trust, Warrington Hospital, Royal Preston Hospital, Aintree University Hospitals NHS Foundation Trust, Aintree University Hospital, National Institute for Health and Care Research
Language: English
Topic: Nosocomial Infections in ICU
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225920707
